UBS Maintains a 'Buy' on Par Pharmaceutical (PRX); Comments From Conference Call

May 9, 2012 12:21 PM EDT Send to a Friend
Get Alerts PRX Hot Sheet
Price: $49.98 --0%

Rating Summary:
    2 Buy, 8 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 24 | Down: 28 | New: 14
Trade PRX Now!
Join SI Premium – FREE
UBS maintains a 'Buy' on Par Pharmaceutical (NYSE: PRX) price target raised from $42 to $48.

Analyst, Ami Fadia's Conference Call highlights: (1) Combined R&D efforts from legacy Par, Anchen and Edict teams have enabled Par to track ahead of its goal of 13-17 filings per year; (2) Mgt. expects ~10-14 new launches in the coming qtrs; (3) Base generic business saw minimum erosion in the quarter with a slight GM expansion; (4) 1Q R&D included $10M for the Dexilant deal and a $2M write down on a pipeline product; (5) While SG&A was light in 1Q, mgt. indicated that it is on track to meet full yr guidance of ~$180M; (6) Management remains confident in its Lovaza application/ court case and is ready for a launch."

UBS adjusts FY12 EPS estimate from $4.03 to $3.96.

For an analyst ratings summary and ratings history on Par Pharmaceutical click here. For more ratings news on Par Pharmaceutical click here.

Shares of Par Pharmaceutical closed at $42.08 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

UBS

Add Your Comment